Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More
Portfolio Pulse from Benzinga Neuro
Bernie Sanders criticized the high pricing of the diabetes drug Ozempic, manufactured by Novo Nordisk (NYSE:NVO), suggesting that Americans are charged 10-15 times more than people in other countries. Sanders, who chairs the Senate HELP Committee, has previously criticized the drug's pricing and considered holding hearings on the issue. Novo Nordisk's CEO agreed to testify before the Senate after Sanders threatened to subpoena the company. Following Sanders' tweet, Novo Nordisk shares closed 2.2% lower.
June 27, 2024 | 1:14 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Bernie Sanders criticized Novo Nordisk's pricing of Ozempic, suggesting Americans pay 10-15 times more than other countries. This led to a 2.2% drop in Novo Nordisk's stock price.
Sanders' criticism of Novo Nordisk's pricing practices for Ozempic has likely led to negative investor sentiment, causing a 2.2% drop in the stock price. The potential for regulatory scrutiny adds to the negative outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100